Macrophage migration inhibitory factor (MIF) inhibitor (IC50
= 7 μ
M); inhibits MIF tautomerase activity in vitro
and in vivo
. Protective against mouse models of streptozotocin-induced diabetes mellitus; blocks anti-inflammatory response following LPS exposure and increases survival. Inhibits airway remodeling in a mouse model of chronic asthma. Cell permeable; orally bioavailable.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
ISO-1 binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis.
Al-Abed et al.
Critical role of macrophage migration inhibitory factor activity in experimental autoimmune diabetes.
Cvetkovic et al.
ISO-1, a macrophage migration inhibitory factor antagonist, inhibits airway remodeling in a murine model of chronic asthma.
Chen et al.
The tautomerase active site of macrophage migration inhibitory factor is a potential target for discovery of novel anti-inflammatory agents.
Lubetsky et al.